FDA Accepts BLA for Ozekibart in Chondrosarcoma, Sets April 2027 PDUFA Date
Summary
The FDA has accepted Inhibrx Biosciences' BLA for ozekibart for chondrosarcoma, setting an April 14, 2027 PDUFA goal date and identifying no filing review issues.
Key Events
-
FDA Accepts BLA for Ozekibart
The U.S. Food and Drug Administration (FDA) has accepted Inhibrx Biosciences' Biologics License Application (BLA) for ozekibart (INBRX-109) for the treatment of unresectable or metastatic conventional chondrosarcoma.
-
PDUFA Goal Date Set
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027, for a decision on ozekibart.
-
No Filing Review Issues Identified
The FDA has not identified any filing review issues at this time, indicating a smooth progression of the application review process.
-
Potential First-in-Class Therapy
If approved, ozekibart would be the first FDA-approved systemic therapeutic for patients with unresectable or metastatic conventional chondrosarcoma, addressing a significant unmet medical need.
Analysis
The FDA's acceptance of the Biologics License Application (BLA) for ozekibart is a critical step towards commercialization. This confirms the application is complete and under active review, moving the drug closer to potential approval. Ozekibart targets a rare and aggressive bone cancer with no approved therapies, making its potential approval a significant event for both patients and the company, establishing a clear timeline for a regulatory decision.
At the time of this filing, INBX was trading at $93.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $13.97 to $155.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.